Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Leukemia & Lymphoma Society and MannKind Corporation have jointly announced the execution of a collaborative research arrangement funded through The Leukemia & Lymphoma Society's Therapy Acceleration Program.
Subscribe to our email newsletter
Therapy Acceleration Program (TAP) is an innovative program intended to advance therapies with high prospects of providing near-term benefit to patients suffering from blood cancers.
The TAP funding will support MannKind’s efforts to develop a novel and highly selective first-in-class targeted tyrosine kinase inhibitor for the treatment of T-cell leukemia and lymphoma. This early development work, if successful, will lead to the initiation of IND-enabling studies.
Alfred Mann, chairman and CEO of MannKind, said: “The sponsorship of The Leukemia & Lymphoma Society (LLS) will help MannKind to advance its development of a potential new blood cancer treatment.”